Findings

What do systematic reviews say?

6 questions · 6 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 16.7%Moderate 5 · 83.3%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Certolizumab pegol vs placebo · Clinical remission
  Certolizumab pegol for induction of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
  RR 1.36 [1.11, 1.66]
  4 studies · 1485 participants
  Moderate
Direct match · question page
- Certolizumab pegol vs placebo · Clinical response
  Certolizumab pegol for induction of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
  RR 1.29 [1.09, 1.53]
  4 studies · 1485 participants
  Moderate
Direct match · question page
- Certolizumab pegol vs placebo · Failure to maintain clinical remission at week 26(1 RCT, 428 participants)
  Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease 2022 · Cochrane Headline outcomes only
  RR 0.73 [0.63, 0.85]
  Studies not reported
  Moderate
Direct match · question page
- Certolizumab pegol vs placebo · Failure to maintain clinical response at week 26(1 RCT, 428 participants)
  Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease 2022 · Cochrane Headline outcomes only
  RR 0.58 [0.48, 0.71]
  Studies not reported
  Moderate
Direct match · question page
- Certolizumab pegol vs placebo · Serious adverse events during remission maintenance treatment(1 RCT, 428 participants) Outcome: occurrence of infection, blood and lymphatic system disorder, immune system disorder, neoplasm, demyelinating disorders, drug‐induced systemic lupus er...
  Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease 2022 · Cochrane Headline outcomes only
  RR 0.84 [0.4, 1.78]
  Studies not reported
  Low

Certolizumab pegol vs placebo

Clinical remission · Patients with active Crohn's disease

Certolizumab pegol probably leads to higher clinical remission compared with placebo (moderate certainty).

1 finding from 1 review

Certolizumab pegol for induction of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.36 [1.11, 1.66]
4 studies · 1485 participants
Moderate

Certolizumab pegol vs placebo

Clinical response · Patients with active Crohn's disease

Certolizumab pegol probably leads to higher clinical response compared with placebo (moderate certainty).

1 finding from 1 review

Certolizumab pegol for induction of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.29 [1.09, 1.53]
4 studies · 1485 participants
Moderate

Certolizumab pegol vs placebo

Serious adverse events · Patients with active Crohn's disease

Certolizumab pegol showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Certolizumab pegol for induction of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.35 [0.93, 1.97]
4 studies · 1485 participants
Moderate

Certolizumab pegol vs placebo

Failure to maintain clinical remission at end of study · people with Crohn's disease who responded to CZP remission‐induction treatment

Certolizumab pegol probably leads to lower failure to maintain clinical remission at week 26(1 RCT, 428… compared with placebo (moderate certainty).

1 finding from 1 review

Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease 2022 · Cochrane Headline outcomes only
RR 0.73 [0.63, 0.85]
Studies not reported
Moderate

Certolizumab pegol vs placebo

Failure to maintain clinical response · people with Crohn's disease who responded to CZP remission‐induction treatment

Certolizumab pegol probably leads to lower failure to maintain clinical response at week 26(1 RCT, 428… compared with placebo (moderate certainty).

1 finding from 1 review

Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease 2022 · Cochrane Headline outcomes only
RR 0.58 [0.48, 0.71]
Studies not reported
Moderate

Certolizumab pegol vs placebo

Any severe adverse event during maintenance treatment · people with Crohn's disease who responded to CZP remission‐induction treatment

Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).

1 finding from 1 review

Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease 2022 · Cochrane Headline outcomes only
RR 0.84 [0.4, 1.78]
Studies not reported
Low